Abstract

The most common cancer in women is breast cancer. Bosom disease subtypes are grouped by histologic elements, including morphology and receptor status. Data on the declaration of estrogen receptor (emergency room), progesterone receptor, and human epidermal development factor receptor 2 (HER2), as well as the multiplication record Ki67 (in beginning phase sickness), are applicable for clinical choices. To further segment the disease into subgroups, stratify risk, or estimate the benefits of interventions, molecular tests are now available. Human epidermal growth factor receptor 2 (HER2) overexpression, the absence of estrogen receptor (ER) and progesterone receptor (PR) expression, and the absence of targeted treatments make triple-negative breast cancer (TNBC) a highly variable condition with poor clinical outcomes. As a result, improved stratification systems that consider intrinsic and clinically relevant differences between TNBC tumors will sharpen treatment strategies and enhance clinical outcomes.